Raydiant Oximetry

Executive Summary

Raydiant Oximetry is a clinical-stage medical device company developing Lumerah™, a noninvasive fetal pulse oximeter designed to directly measure fetal oxygen levels during labor and delivery. The device leverages advanced biophotonics and machine learning to provide clinicians with a more reliable tool for assessing fetal well-being, with the goal of reducing unnecessary cesarean sections and improving outcomes for mothers and babies. Founded in 2018 and headquartered in Mountain View, California, the company is currently in the pre-clinical stage, focusing on technology refinement and preparation for first-in-human studies. Despite limited public funding information, Raydiant Oximetry addresses a significant unmet need in obstetrics: current fetal monitoring methods (e.g., electronic fetal monitoring) have high false-positive rates for hypoxia, leading to unnecessary interventions. Lumerah aims to offer continuous, accurate oxygenation data, potentially transforming intrapartum care. The company's technology has the potential to disrupt the $X billion fetal monitoring market, but it faces technical and regulatory challenges. Noninvasive fetal oximetry is complex due to signal interference from maternal tissues, and the FDA pathway for novel medical devices is rigorous. Raydiant Oximetry will likely require substantial capital to navigate clinical trials and regulatory approval. Key upcoming catalysts include securing Series A funding, initiating first-in-human feasibility studies, and obtaining FDA breakthrough device designation. The success of these milestones will determine the company's trajectory. Given the early stage, the conviction score is moderate, reflecting the technology's promise but acknowledging execution risk.

Upcoming Catalysts (preview)

• Q1 2027Series A Funding Announcement60% success
• Q3 2027Initiation of First-in-Human Feasibility Study50% success
• Q4 2026FDA Breakthrough Device Designation70% success